vimarsana.com

Latest Breaking News On - Terufumi kato - Page 1 : vimarsana.com

Investigators Deliver Updates on Evolving Clinical Trials Evaluating ADCs in Lung Cancer

Melissa L. Johnson, MD, Terufumi Kato, MD, and Pasi A. Jänne, MD, PhD, present updates from the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.

United-states
Kanagawa
Fukushima
Japan
Massachusetts
Dana-farber-cancer-institute
Singapore
Boston
Yokohama
Tennessee
Ifinatamab-deruxtecan
Melissal-johnson

Dr. Kato on the Rationale For Investigating Dato-DXd Plus Durvalumab and Carboplatin in Advanced NSCLC

Terufumi Kato, MD, Terufumi Kato, MD, Chief Physician, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, discusses the ongoing investigation of datopotamab deruxtecan in combination with durvalumab and carboplatin as a first-line treatment for patients with advanced metastatic non–small cell lung cancer.

Kanagawa
Fukushima
Japan
Yokohama
Terufumi-kato
Kanagawa-cancer-center
Department-of-thoracic-oncology
Chief-physician
Thoracic-oncology
Infinatamab-deruxtecan
I-dxd-ds-7300-
2023-iaslc-world-conference-on-lung-cancer

New Drug Effective Against Lung Cancers Caused by Common Genetic Error

/PRNewswire/ A new drug reduced tumor size in patients who have lung cancer patients with a specific, disease-causing change in the gene KRAS, a study found..

New-york
United-states
Australia
Memorial-sloan-kettering-cancer-center
Japan
Fox-chase-cancer-center
Pennsylvania
Yokohama
Kanagawa
Texas
Thousand-oaks
California

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.